Menu

CME Corner

Program Detail

Release Date: October-01-18
Credit Expiration Date: October-01-19

Faculty

Faculty Presenter
Carol H. Wysham, MD, FACP, FACE
Clinical Professor of Medicine
University of Washington School of Medicine
Section Head, Rockwood Center for Diabetes and Endocrinology
Spokane, WA

Additional Content Development Faculty
John L. Leahy, MD
Co-Chief, Division of Endocrinology, Diabetes, and Metabolism
Professor of Medicine
University of Vermont College of Medicine
Director, Vermont Regional Diabetes Center
Burlington, VT

Serena Cardillo, MD
Associate Professor of Clinical Medicine
Division of Endocrinology, Diabetes, and Metabolism
Perelman School of Medicine at the University of Pennsylvania
Perelman Center for Advanced Medicine
Philadelphia, PA

Carrie M. Burns, MD
Associate Professor of Clinical Medicine
Division of Endocrinology, Diabetes, and Metabolism
Perelman School of Medicine at the University of Pennsylvania
Perelman Center for Advanced Medicine
Philadelphia, PA

Credit Hours

1.0

Medium

Online Presentation

Program Description

Type 2 diabetes (T2D) is a chronic, highly prevalent disease. Despite the availability of many treatment options, including new insulin formulations that have the potential to simplify treatment regimens, improve treatment adherence, and provide clinical benefit, patients often have poor glycemic control. This activity will examine the role of insulin therapy in the management of T2D.

Program Developer/Facilitator


.

Target Audience

Endocrinologists, primary care/internal medicine physicians, and other clinicians including pharmacists, nurse practitioners (NPs), physician assistants (PAs), nurses, and diabetes educators involved in the management of patients with T2D.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Initiate and adjust insulin therapy in appropriate patients with T2D who have not achieved glycemic control on non-insulin therapy.
  2. Develop strategies to overcome patient-related adherence barriers to the use of insulin in patients with T2D.
  3. Summarize the current evidence-based practice guidelines for glycemic control in patients with T2D.
  4. Describe the benefits and risks of currently approved insulin therapies.

Disclosures

Dr. Wysham has disclosed the following:
Consultant: Astra Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi
Speaker Bureau: Astra Zeneca, Boehringer Ingelheim, Insulet, Janssen, Novo Nordisk, and Sanofi
Advisory Board: Abbott, Janssen, Novo Nordisk, and Sanofi

Dr. Leahy has disclosed the following:
Advisory Board: Novo Nordisk, Merck, Sanofi, Janssen, Valeritas

Dr. Cardillo has no relevant affiliations or financial relationships with a commercial interest to disclose.

Dr. Burns has no relevant affiliations or financial relationships with a commercial interest to disclose.

The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-18-113-H01-P; 1.0 contact hour (.10 CEU).

Commercial Support Statements

Supported by educational grants from Sanofi US, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Certificate Fee

$0.00

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS